WO2008090678A1 - 新規ペプチド - Google Patents

新規ペプチド Download PDF

Info

Publication number
WO2008090678A1
WO2008090678A1 PCT/JP2007/073026 JP2007073026W WO2008090678A1 WO 2008090678 A1 WO2008090678 A1 WO 2008090678A1 JP 2007073026 W JP2007073026 W JP 2007073026W WO 2008090678 A1 WO2008090678 A1 WO 2008090678A1
Authority
WO
WIPO (PCT)
Prior art keywords
novel peptide
activity
peptide
energy
circulatory function
Prior art date
Application number
PCT/JP2007/073026
Other languages
English (en)
French (fr)
Inventor
Motoo Yamasaki
Noriyuki Takahashi
Naoto Minamino
Kazuki Sasaki
Toshifumi Takao
Yoshinori Satomi
Yoichi Ueta
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Japan As Represented By The President Of National Cardiovascular Center
Osaka University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd., Japan As Represented By The President Of National Cardiovascular Center, Osaka University filed Critical Kyowa Hakko Kirin Co., Ltd.
Priority to JP2008554979A priority Critical patent/JPWO2008090678A1/ja
Priority to US12/524,036 priority patent/US20100075343A1/en
Priority to EP07832741A priority patent/EP2123751A4/en
Publication of WO2008090678A1 publication Critical patent/WO2008090678A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

本発明により、エネルギー調節活性または循環機能調節活性を有する新規なペプチドが提供される。本発明のペプチドはエネルギー調節活性または循環機能調節活性を有し、摂食障害や循環系疾患の治療に有用である。
PCT/JP2007/073026 2007-01-25 2007-11-29 新規ペプチド WO2008090678A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008554979A JPWO2008090678A1 (ja) 2007-01-25 2007-11-29 新規ペプチド
US12/524,036 US20100075343A1 (en) 2007-01-25 2007-11-29 Novel peptides
EP07832741A EP2123751A4 (en) 2007-01-25 2007-11-29 NEW PEPTIDE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007014455 2007-01-25
JP2007-014455 2007-01-25

Publications (1)

Publication Number Publication Date
WO2008090678A1 true WO2008090678A1 (ja) 2008-07-31

Family

ID=39644256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/073026 WO2008090678A1 (ja) 2007-01-25 2007-11-29 新規ペプチド

Country Status (4)

Country Link
US (1) US20100075343A1 (ja)
EP (2) EP2123751A4 (ja)
JP (1) JPWO2008090678A1 (ja)
WO (1) WO2008090678A1 (ja)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS59140885A (ja) 1983-01-13 1984-08-13 マツクス・プランク・ゲゼルシヤフト・ツア・フエルデルング・デア・ヴイツセンシヤフテン・エ−・フアウ 植物細胞ゲノムへの発現可能な遺伝子の導入法
JPS6070080A (ja) 1983-02-24 1985-04-20 レイクスニベルシテイト　ライデン 双子葉植物の染色体への外来性ｄνａの組込方法
JPS60251887A (ja) 1984-05-11 1985-12-12 ノバルティス　アクチエンゲゼルシャフト 植物のプロトプラストの形質転換法
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JPH01102096A (ja) 1987-10-15 1989-04-19 Sanwa Kagaku Kenkyusho Co Ltd モチリン様活性を有するポリペプチド、その発現用微生物及び該ポリペプチドの製法
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994000977A1 (en) 1992-07-07 1994-01-20 Japan Tobacco Inc. Method of transforming monocotyledon
WO1994023021A1 (en) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
JP2517813B2 (ja) 1990-05-29 1996-07-24 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 生きている細胞に生物学的物質を導入するための改良された方法および装置
JP2606856B2 (ja) 1986-12-05 1997-05-07 アグラシータス 生細胞中に遺伝物質担持担体粒子を注入するための装置
WO2002010371A1 (fr) 2000-08-01 2002-02-07 Kyowa Hakko Kogyo Co., Ltd. Peptide acitf sur le plan physiologique et utilisation de celui-ci
WO2002082075A2 (de) 2001-04-06 2002-10-17 Biovision Ag Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
MXPA02000680A (es) 1999-07-21 2002-07-02 Amgen Inc Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
US7749716B2 (en) * 2004-05-18 2010-07-06 Vermilllion, Inc. Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS59140885A (ja) 1983-01-13 1984-08-13 マツクス・プランク・ゲゼルシヤフト・ツア・フエルデルング・デア・ヴイツセンシヤフテン・エ−・フアウ 植物細胞ゲノムへの発現可能な遺伝子の導入法
JPS6070080A (ja) 1983-02-24 1985-04-20 レイクスニベルシテイト　ライデン 双子葉植物の染色体への外来性ｄνａの組込方法
JPS60251887A (ja) 1984-05-11 1985-12-12 ノバルティス　アクチエンゲゼルシャフト 植物のプロトプラストの形質転換法
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JP2606856B2 (ja) 1986-12-05 1997-05-07 アグラシータス 生細胞中に遺伝物質担持担体粒子を注入するための装置
JPH01102096A (ja) 1987-10-15 1989-04-19 Sanwa Kagaku Kenkyusho Co Ltd モチリン様活性を有するポリペプチド、その発現用微生物及び該ポリペプチドの製法
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JP2517813B2 (ja) 1990-05-29 1996-07-24 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 生きている細胞に生物学的物質を導入するための改良された方法および装置
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994000977A1 (en) 1992-07-07 1994-01-20 Japan Tobacco Inc. Method of transforming monocotyledon
WO1994023021A1 (en) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO2002010371A1 (fr) 2000-08-01 2002-02-07 Kyowa Hakko Kogyo Co., Ltd. Peptide acitf sur le plan physiologique et utilisation de celui-ci
WO2002082075A2 (de) 2001-04-06 2002-10-17 Biovision Ag Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
"Antibodies, A Laboratory manual", 1988, COLD SPRING HARBOR LABORATORY
"Biochemistry Experimental Course", vol. 1, article "Chemistry of Protein IV-Chemical Modification and Peptide Synthesis"
"Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
"Peptide Synthesis", vol. 14, 1991, HIROKAWA SHOTEN, article "The sequel of Development of Pharmaceuticals"
AGRIC. BIOL. CHEM., vol. 48, 1984, pages 669
AGRIC. BIOL. CHEM., vol. 53, 1989, pages 277
AIMOTO, S. ET AL.: "Organic Synthesis (Yuki Gosei) IV, Acid, Amino acid and Peptide", vol. 22, 1999, article "Experimental Chemical Course (Jikken Kagaku Koza"
ANAL. BIOCHEM., vol. 222, 1994, pages 19
BIO/TECHNOLOGY, vol. 6, 1988, pages 47
BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1
CANU N. ET AL.: "Cloning, Structural Organization Analysis, and Chromosomal Assignment of the Human Gene for Neurosecretory Protein VGF", GENOMICS, vol. 45, no. 2, 1997, pages 443 - 446, XP004434167 *
CELLULAR AND MOLECULAR NEUROBIOLOGY, vol. 24, no. 4, 2004, pages 517 - 533
CURR. TOPICS. MICROBIOL. IMMUNOL., vol. 81, 1978, pages 1
CYTOTECHNOLOGY, vol. 1, 1990, pages 133
CYTOTECHNOLOGY, vol. 3, 1990, pages 133
EMBO JOURNAL, vol. 8, no. 8, 1989, pages 2217 - 2223
ENDOCRINOLOGY, vol. 135, no. 6, 1994, pages 2742 - 2748
ENDOCRINOLOGY, vol. 140, no. 8, 1999, pages 3727 - 3735
EUROP. J. IMMUNOL., vol. 511, 1976
EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 20, no. 11, 2004, pages 3035 - 3040
FIELDS, G. B.: "Methods in Enzymology", vol. 289, 1997, ACADEMIC PRESS, article "Solid-Phase Peptide Synthesis"
GENE, vol. 17, 1982, pages 107
GENES DEVELOP., vol. 4, 1990, pages 1288
GENOMICS, vol. 45, no. 2, 1997, pages 443 - 446
IGAKU SHOIN: "Antibodies - A Laboratory Manual", 1976, COLD SPRING HARBOR LABORATORY, article "Enzyme-linked Immunosorbent Assay"
INT. J. PEPT. PROTEIN RES., vol. 35, 1990, pages 161 - 214
IZUMIYA, N. ET AL.: "Fundamentals and Experiments of Peptide Synthesis", 1985, MARUZEN
IZUMIYA, N.; KATO, T. ET AL., FUNDAMENTALS AND EXPERIMENTS OF PEPTIDE SYNTHESIS (PEPTIDE GOSEI NO KISO TO JIKKEN), 1985
J. BACTERIOLOGY, vol. 153, 1983, pages 163
J. BIOCHEM., vol. 101, 1987, pages 1307
J. BIOL. CHEM., vol. 264, 1989, pages 17619
J. IMMUNOL., vol. 123, 1979, pages 1548
JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES AND APPLICATIONS, vol. 754, no. 2, 2001, pages 357 - 367
JOURNAL OF NEUROCHEMISTRY, vol. 81, no. 3, 2002, pages 565 - 574
LEVI A. ET AL.: "Processing, Distribution, and Function of VGF, a Neuronal and Endocrine Peptide Precursor: Honoring John William Daly, Part II", CELLULAR AND MOLECULAR NEUROBIOLOGY, vol. 24, no. 4, 2004, pages 517 - 533, XP019275731 *
LIU J.W. ET AL.: "Peptide V: a VGF-derived neuron peptide purified from bovine posterior pituitary", ENDOCRINOLOGY, vol. 135, no. 6, 1994, pages 2742 - 2748, XP000953047 *
METHODS. IN ENZYMOL., vol. 194, 1990, pages 182
MOLECULAR & GENERAL GENETICS, vol. 168, 1979, pages 111
NATURE, vol. 195, 1962, pages 788
NATURE, vol. 256, 1975, pages 495
NATURE, vol. 276, 1978, pages 269
NATURE, vol. 329, 1987, pages 840
NEURON, vol. 23, no. 3, 1999, pages 537 - 548
OHNO, M. ET AL.: "Chemical Modification of Proteins", vol. 12, 13, 1981, JAPAN SCIENTIFIC SOCIETIES PRESS, article "Experimental Methods in Biological Chemistry"
PENNINGTON, M. W.; DUNN, B. M.: "Methods in Molecular Biology", vol. 35, 1994, HUMANA PRESS, article "Peptide Synthesis Protocols"
PROC. NATL. ACAD. SCI, vol. 69, 1972, pages 2110
PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 1929
PROC. NATL. ACAD. SCI., vol. 75, 1978, pages 1929
PROC. NATL. ACAD. SCI., vol. 84, 1987, pages 7413
PROC. NATL. ACAD. SCI., vol. 86, 1989, pages 8227
PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES, vol. 103, no. 39, 2006, pages 14584 - 14589
SCIENCE, vol. 122, 1952, pages 501
SCIENCE, vol. 229, no. 4711, 1985, pages 393 - 395
See also references of EP2123751A4 *
SEUNG HAHM ET AL.: "Targeted Deletion of the Vgf Gene Indicates that the Encoded Secretory Peptide Precursor Plays a Novel Role in the Regulation of Energy Balance", NEURON., vol. 23, no. 3, 1999, pages 537 - 548, XP000952987 *
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
UETA ET AL., ENDOCRINOLOGY, vol. 146, 2005, pages 406 - 413
VIROLOGY, vol. 52, 1973, pages 456
VIROLOGY, vol. 8, 1959, pages 396
W. H. FREEMAN; COMPANY, A LABORATORY MANUAL, 1992
W.H. FREEMAN; COMPANY, LABORATORY MANUAL, 1992

Also Published As

Publication number Publication date
JPWO2008090678A1 (ja) 2010-05-13
EP2316939A2 (en) 2011-05-04
EP2123751A1 (en) 2009-11-25
EP2123751A4 (en) 2010-06-02
US20100075343A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
HK1215960A1 (zh) 用於治療視網膜變性疾病的改良方式
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
UA98629C2 (ru) Соединения и способ модуляции киназ
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
EP2068768A4 (en) METHOD AND SYSTEM FOR ENHANCING THE DIASTOLIC FUNCTION OF THE HEART
WO2006127900A3 (en) Tl1a in the treatment of disease
IL178815A0 (en) The treatment of respiratory disease
EP1789034A4 (en) COMPOUNDS HAVING A DIPHENYL STRUCTURE FOR THE TREATMENT OF IMMUNE DISEASES
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
GB0410399D0 (en) The treatment of respiratory disease
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1753446A4 (en) ALPHA-1 GLYCOPROTEIN ACID FOR THE TREATMENT OF DIABETES
GB2423072B (en) Regulating the administration of a clinical procedure
WO2006095173A3 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof
WO2008090678A1 (ja) 新規ペプチド
GB0523964D0 (en) The treatment of ophthalmic diseases
AU2004100684A4 (en) SafePlan
WO2006119912A3 (de) Verwendung von histonen zu therapeutischen zwecken
WO2009024763A3 (en) Combination therapy
WO2006134591A3 (en) Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases
AU2005901420A0 (en) Diagnosis and treatment of disorders
AU2005903146A0 (en) Methods for the diagnosis and treatment of epilepsy
AU2005906446A0 (en) Methods for the diagnosis and treatment of epilepsy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07832741

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008554979

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007832741

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12524036

Country of ref document: US